Messing up with traffic: Different effects of antipsychotic agents on glutamate receptor complexes in vivo

Molecular Pharmacology

Volumn 73, Issue 5, 2008, Pages 1339-1342

  Del'guidice, Thomas ^a   Beaulieu, Jean Martin ^a  

^a CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; DOPAMINE RECEPTOR; GLUTAMATE RECEPTOR; HALOPERIDOL; N METHYL DEXTRO ASPARTATE GLUTAMATE RECEPTOR; NEUROLEPTIC AGENT; PROTEIN KINASE (CALCIUM,CALMODULIN); SEROTONIN 2 RECEPTOR; UNCLASSIFIED DRUG; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

COGNITIVE DEFECT; DRUG EFFECT; DRUG MECHANISM; HUMAN; IN VIVO STUDY; NERVE CELL PLASTICITY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; ANIMAL; ENZYMOLOGY; METABOLISM; NOTE; PREFRONTAL CORTEX; PROTEIN TRANSPORT; RAT; SYNAPTIC TRANSMISSION;

ANIMALS; ANTIPSYCHOTIC AGENTS; PREFRONTAL CORTEX; PROTEIN TRANSPORT; RATS; RECEPTORS, GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPTIC TRANSMISSION;

EID: 42449094187     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.046540     Document Type: Review

References (28)

1. Bayer KU, LeBel E, McDonald GL, O'Leary H, Schulman H, and De Koninck P (2006) Transition from reversible to persistent binding of CaMKII to postsynaptic sites and NR2B. J Neurosci 26:1164-1174.
2. Beaulieu JM, Gainetdinov RR, and Caron MG (2007) The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci 28:166-172.
3. Beaulieu JM, Marion S, Rodriguiz RM, Medvedev IO, Sotnikova TD, Ghisi V, Wetsel WC, Lefkowitz RJ, Gainetdinov RR, and Caron MG (2008) A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 132:125-136.
4. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, and Caron MG (2005) An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122:261-273.
5. Beaulieu JM, Sotnikova TD, Yao WD, Kockeritz L, Woodgett JR, Gainetdinov RR, and Caron MG (2004) Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A 101:5099-5104, .
6. Castner SA, Williams GV, and Goldman-Rakic PS (2000) Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science 287:2020-2022.
7. Cepeda C and Levine MS (2006) Where do you think you are going? The NMDA-D1 receptor trap. Sci STKE 2006:pe20.
8. Creese I, Burt DR, and Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481-483.
9. Di Pietro NC and Seamans JK (2007) Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action. Pharmacopsychiatry 40 (Suppl 1):S27-S33.
10. Esteban JA, Shi SH, Wilson C, Nuriya M, Huganir RL, and Malinow R (2003) PKA phosphorylation of AMPA receptor subunits controls synaptic trafficking underlying plasticity. Nat Neurosci 6:136-143.
11. Fumagalli F, Frasca A, Racagni G and Riva MA (2008) Dynamic regulation of glutamatergic postsynaptic activity in rat prefrontal cortex by repeated administration of antipsychotic drugs. Mol Pharmacol 73:1484-1490.
12. Gardoni F, Frasca A, Zianni E, Riva MA, Di Luca M, and Fumagalli F (2008) Repeated treatment with haloperidol, but not olanzapine, alters synaptic NMDA receptor composition in rat striatum. Eur Neuropsychopharmacol, in press.
13. Garner CC and Kindler S (1996) Synaptic proteins and the assembly of synaptic junctions. Trends Cell Biol 6:429-433.
14. Haupt DW and Kane JM (2007) Metabolic risks and effects of atypical antipsychotic treatment. J Clin Psychiatry 68:e24.
15. 2+/calmodulin- dependent protein kinase II: the role of structure and autoregulation in cellular function. Annu Rev Biochem 71:473-510.
16. Idänpään-Heikkilä J, Alhava E, Olkinuora M, and Palva I (1975) Letter: Clozapine and agranulocytosis. Lancet 2:611.
17. Kapur S, and Remington G (2001) Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 52:503-517.
18. Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Rock SL, Woolson S, Tohen M, Tollefson GD, et al. (2006) Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol Psychiatry 59:97-105.
19. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, et al. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223.
20. Meltzer HY (1991) The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17:263-287.
21. Missale C, Nash SR, Robinson SW, Jaber M, and Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78:189-225.
22. Mohn AR, Gainetdinov RR, Caron MG, and Koller BH (1999) Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98:427-436.
23. Oosthuizen P, Emsley R, Jadri Turner H, and Keyter N (2004) A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis. Int J Neuropsychopharmacol 7:125-131.
24. Peineau S, Taghibiglou C, Bradley C, Wong TP, Liu L, Lu J, Lo E, Wu D, Saule E, Bouschet T, et al. (2007) LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 53:703-717.
25. Roth BL, Sheffler DJ, and Kroeze WK (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3:353-359.
26. Sharp FR, Tomitaka M, Bernaudin M, and Tomitaka S (2001) Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia? Trends Neurosci 24:330-334.
27. Sheng M, and Hoogenraad CC (2007) The postsynaptic architecture of excitatory synapses: a more quantitative view. Annu Rev Biochem 76:823-847.
28. Yao WD, Gainetdinov RR, Arbuckle MI, Sotnikova TD, Cyr M, Beaulieu JM, Torres GE, Grant SG, and Caron MG (2004) Identification of PSD-95 as a regulator of dopamine-mediated synaptic and behavioral plasticity. Neuron 41:625-638.